Navigation Links
ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ --

- Professor Desire Collen Will Remain as Chairman of the Board and Scientific Advisor

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces today that Patrik De Haes, MD, currently Chief Operating Officer, has been appointed to succeed Professor Desire Collen as the Company's new Chief Executive Officer on September 1, 2008. At the next General Shareholders Meeting Dr. De Haes will be proposed to become a member of the Board of Directors of ThromboGenics. In the mean time, he will be invited to the Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors. This new structure ensures the continuity of ThromboGenics' senior management.

Dr. De Haes, 50, has considerable international experience across the biotechnology and healthcare sectors spanning more than 20 years. For the last 18 months, Dr. De Haes has been ThromboGenics' Chief Operating Officer overseeing the Company's daily operations. During this period, he has been a key member of the management team that has achieved a number of transforming milestones for ThromboGenics. These include initiating the clinical development of the Company's unique anti-cancer agent TB-403, and the subsequent development deal for potentially up to EUR500 million with Roche. Dr. De Haes has also been a major contributor to the development strategy of ThromboGenics' lead product, microplasmin, which the Company plans to advance into Phase III clinical trials in early 2009 for the treatment of a number of important eye diseases.

Prior to joining ThromboGenics, Dr. De Haes was Head of the Global Insulin Infusion Business at Roche Diagnostics in Bern, Switzerland, and a member of the Executive Commit
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
2. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
3. ThromboGenics N.V. - Business Update
4. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
5. ThromboGenics Announces 2007 Full Year Results
6. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
9. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
10. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
11. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... On April 19th the Center for Disease ... the growing antibiotic resistant bacteria that may be lurking ... study were released late last month showing higher antibiotic ... years. For those suffering from bacteria driven acne, Probiotic ... in food, may eventually help breed acne causing bacteria. ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... developing DCVax ® personalized immune therapies for solid ... exhibit at this year,s American Society Of Clinical Oncology ... highlight its leadership role in immune therapy.  ... annual meeting is the pre-eminent conference focused on clinical ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Expression Genetics, Inc.,(EGEN) announced today that ... selected as one of the Top 10 ... strategic partnering. The selection was made by,an ... leading,provider of business information products and services ...
... Development Efforts, SALT LAKE CITY, Sept. 5 ... development of molecular diagnostic and motion preserving,technologies in ... Ross has,joined the executive management team as the ... this new role, Ross will oversee Axial Biotech,s ...
... Ind., Sept. 4 Zimmer Holdings, Inc.,(NYSE: ZMH ... have,agreed to acquire the Abbott Spine business from Abbott ... to fund the purchase price,from cash on hand and ... expected to close in the fourth quarter of 2008. ...
Cached Biology Technology:Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 2Expression Genetics' EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover 3Axial Biotech appoints new Vice President of Strategic Initiatives 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 2Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 3Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology 4
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... discovery of potential environmental and human health effects ... each year has led scientists to recommend stronger ... of lithium-ion (Li-ion) battery materials. That,s the conclusion ... Environmental Science & Technology . , Oladele ... batteries have become mainstays for powering everything from ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... forests that add the most new growth each year -- ... Survey (USGS) study published in a recent issue of the ... forests will respond to ongoing and future environmental changes. , ... world¹s most productive forests may be those likely to respond ...
... DuPont polymer derived from a biological source, has been ... China Central Television (CCTV) as "Most Visionary Innovation" at ... DuPontTM Sorona® will receive the 2005 "New ... Global Plastics and Environmental Conference, sponsored by the Society ...
... core cellular mechanisms of sleep, researchers at University of ... a single gene mutation that has a powerful effect ... In its normal state, the Drosophila (fruit fly) gene, ... flow of potassium into cells, a process that critically ...
Cached Biology News:Live fast, die young true for forests too 2DuPont's first biologically derived polymer receives global recognition 2Wisconsin researchers identify sleep gene 2Wisconsin researchers identify sleep gene 3Wisconsin researchers identify sleep gene 4
MSE ANTI CAN. CD3:FITC/RAT ANTI CD4:RPE...
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
Biology Products: